The international, randomized Phase 3 ASPIRE trial evaluated Kyprolis in combination with lenalidomide and dexamethasone, versus lenalidomide and dexamethasone alone, in patients with relapsed or refractory multiple myeloma following treatment with one to three prior regimens.
ASPIRE demonstrated that the addition of Kyprolis to lenalidomide and dexamethasone reduced the risk of death by 21% versus lenalidomide and dexamethasone alone and extended OS by 7.9 months in patients with relapsed or refractory multiple myeloma..
Amgen discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.
AstraZeneca announces grant of PRIME eligibility by EMA for MEDI8897
AstraZeneca reports grant of Breakthrough Therapy Designation by US FDA for MEDI8897
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
Valbiotis Expands Board of Directors with the Appointment of Murielle Cazaubiel
AstraZeneca's Forxiga receives positive opinion from EU CHMP
Alexion, Caelum Biosciences Team to Develop Targeted Therapy for Light Chain Amyloidosis
Inotrem Extends Its License Agreement for the Biomarker Soluble TREM-1 to Cardiovascular Diseases